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Abstract  
The macrocyclic lactone (ML) drugs are central to the control of equine strongyles but recent international 
reports raise concerns about reduced efficacy of these drugs against cyathostomins. The objectives of the 
present study were firstly, to evaluate the efficacy of ML drugs against cyathostomins on a cross-section of 
Australian horse farms, and secondly, to determine the egg reappearance period (ERP) following treatment 
of horses with MLs. A total of 419 horses on 43 properties were treated orally with ivermectin, abamectin or 
moxidectin, at recommended dose rates and drug efficacy was determined using the faecal egg count 
reduction test. Efficacy of 100% at 14 days post-treatment was reported on all of the 43 farms. ERP following 
ivermectin treatment was 6 weeks on two properties and ERP following moxidectin treatment was 12 weeks 
on a third property. These ERPs are shorter than those reported at the time of commercial release of these 
drugs which likely reflects changing drug susceptibility of the cyathostomin populations tested. Ongoing 
surveillance of drug efficacy and ERPs should be part of an integrated management approach to equine 
worm control that prioritises the preservation of anthelmintic efficacy. 
 
Keywords: Ivermectin, macrocyclic lactones, cyathostomins, strongyles, resistance, egg reappearance 
period 
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1. Introduction 
Due to favourable climatic conditions in many regions (particularly coastal regions) of Australia, cyathostomin 
worms present an ongoing threat to horse health. Although generally less pathogenic than large strongyles, 
cyathostomins can cause significant disease. In addition to the larval cyathostominosis syndrome associated 
with mass emergence of encysted larvae, characterised by diarrhoea and weight loss, cyathostomins have 
also been associated with anorexia and colic (Love et al., 1999). Given the impact of these parasites, there 
is a need to manage the use of effective anthelmintics to delay the emergence and spread of drug resistance 
(Matthews, 2014).  
 
Drugs available to treat cyathostomins in Australia include benzimidazoles (BZs), macrocyclic lactones (MLs) 
and tetrahydropyrimidines (THPs). Suppressive treatment programs throughout the 1960’s, 70’s and 80’s 
used BZs to target Strongylus vulgaris and other large strongyles but led to widespread BZ-resistance 
among cyathostomin populations (Kaplan and Vidyashankar, 2012). BZ-based products, sometimes in 
combination with other drug groups such as THPs, remain widely available in Australia. ML drugs, including 
ivermectin (IVM), abamectin (ABM) and moxidectin (MOX), currently constitute more than 50% of the equine 
anthelmintic products registered in Australia (Public Chemical Registration Information System Search, 
Australian Pesticides and Veterinary Medicines Authority). MOX has a prolonged anthelmintic effect 
compared to IVM and ABM, and greater efficacy against mucosal stages of cyathostomins (Bairden et al., 
2006). The third drug class for worm control in equines, the THPs, includes pyrantel and morantel. Both are 
included in a range of combination anthelmintic products with either MLs or BZs, however, neither are 
currently available as single-active products. This very limited selection of effective chemical treatments for 
cyathostomins, and the apparent absence of new drug classes under development for the equine market, 
underlines the importance of sustaining the efficacy of the ML drugs.  
 
An essential part of managing ML resistance is proactively monitoring drug efficacy, a practice advised but 
seldom undertaken on Australian properties. The emergence of ML resistance among cyathostomins was 
predicted almost two decades ago by Sangster (1999), but reports of resistance, as measured by the faecal 
egg count reduction test (FECRT), are still scarce in the literature. Since the first suspected case was 
reported from the UK following treatment of donkeys with MOX (Trawford et al., 2005), reports from Brazil 
(Molento et al., 2008; Canever et al., 2013), the UK (Relf et al., 2014), Italy (Traversa et al., 2009), Germany 
(Von Samson-Himmelstjerna et al., 2005) and New Zealand (Bishop et al., 2014) have demonstrated a 
reduced efficacy of MLs against cyathostomins in FECRTs. More common are reports of shortened egg 
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reappearance periods (ERPs) (von Samson-Himmelstjerna et al., 2007; Dudeney et al., 2008; Molento et al., 
2008; Lyons et al., 2008b; Rossano et al., 2010; Lyons et al., 2011; Lyons and Tolliver, 2013), and these are 
considered evidence of a shift in ML-sensitivity towards resistance. Critical tests have shown a reduced IVM 
efficacy of only 0-16% against luminal L4 stages (Lyons et al., 2009; Lyons et al., 2010; Lyons and Tolliver, 
2013), thereby shortening the time taken for egg shedding to recommence following treatment. 
 
There are comparatively few investigative reports into anthelmintic resistance among cyathostomins on 
Australian horse properties. Since Pook and co-workers (2002) reported a 100% FECR following treatment 
of horses with IVM on 7 NSW properties (n ≥ 4 horses), there has been only a single Australian case report 
of suspected ML resistance involving an individual horse (Edward and Hoffmann, 2008). In that case, 
monthly faecal egg counts (FECs) were performed on a 24-year-old horse that was treated 7 times within a 
13-month period using various ML worming products. Although FECs were not performed within the 
recommended time frame of 10-14 days post-treatment, as per FECRT guidelines, the study most notably 
reported a count of >2000 epg 3-4 weeks following one IVM treatment and an increase from 200 to 500 epg 
3 weeks after a MOX treatment. FEC results of another two horses on the same property were not discussed 
in detail and the authors reported no evidence of reduced efficacy on 9 other properties investigated. Without 
further investigations, this case should be considered as anecdotal evidence only. 
 
Australian contributions to the global dataset on anthelmintic efficacy against equine helminth populations 
are scarce. We report here the results of a large survey of ML efficacy across a broad cross-section of 
Australian equine properties. 
 
2. Materials and methods 
2.1. Participating farms 
A variety of strategies were used to purposively recruit equine properties. Participants were recruited based 
on their ability to provide a minimum of 10 horses for pre-treatment testing and willingness to perform 
collections from individual horses on 2 separate occasions. Publicly listed horse studs or stables were 
contacted directly. Articles were published in equine magazines and newsletters calling for suitable 
participants, and social media was also utilised to inform horse owners of the study and call for suitable 
participants. A total of 43 properties were recruited to participate in the study during 2012 and 2013, and 
were located in regions across four Australian States (Queensland n = 23 properties, New South Wales n = 
13, Victoria n = 4, and South Australia n = 3). The number of horses on each farm included in the FECRT 
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ranged from 6 to 15 (median 10) and the total number of horses examined in the study was 419. Age data 
was provided for 322 of the 419 samples. Age of horses ranged from 3 months up to 37 years of age (mean 
= 8.8 years, median = 7.0 years). Animal ethics approval for the project was granted by the University of 
Queensland’s animal ethics committee (approval number ANFRA/148/12). 
 
Three of the recruited QLD properties (referred to as properties A, B and C) were selected to also undergo 
an extended period of FEC testing to measure ERP. These properties were all located in the same region of 
southeast QLD and were selected based on their managers’ willingness to comply with the extended weekly 
sampling protocol. Properties A, B and C differed in their anthelmintic treatment histories and the ages of 
horses (Table 1).  
 
Table 1. Summary of 3 equine properties (A, B and C) recruited to measure strongylid egg reappearance 
period. 
Property A B C 
No. of horses 6 18 6 
Age Range 
Mature/Aged 
12 – 30 yrs 
Weanlings 
25 – 35 weeks 
Mostly mature 
3 – 25 yrs 
Breed Mixed breeds 
Australian Stock Horse 
crosses 
Mixed breeds 
Anthelmintic treatment 
history 
Infrequent (1-2 ML 
treatments/yr) over 
previous decade 
Frequent (4+) ML 
treatments per year over 
previous decade 
Infrequent (1-2 ML 
treatments/yr) over 
previous decade 
Time since previous 
anthelmintic treatment* 
16 weeks 12 weeks 12 weeks 
Grazing management 
Set stocked, 
continuously grazed 
together on same 
pasture 
Set stocked, 
continuously grazed 
together on same 
pasture 
Set stocked, 
continuously grazed 
together on same 
pasture 
* Previous treatments were IVM or ABM 
 
2.2 Faecal Egg Count Reduction Test and Determination of Egg Reappearance Period 
The FECRT was carried out in accordance with the World Association for the Advancement of Veterinary 
Parasitology (WAAVP) guidelines for horses (Coles et al., 1992). FECs were performed using a modified 
McMaster technique with a lower detection limit of <10 epg (range 6.2 - 7.5 epg) and a Whitlock Universal 
Slide (J A Whitlock & Co., Eastwood, Australia).  
 
On day 0, pre-treatment samples were collected from all available horses prior to administration of a 
commercial equine anthelmintic containing an active ingredient from the ML class (ivermectin, 0.2 mg/kg, 29 
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properties; abamectin, 0.2 mg/kg, 10 properties; or moxidectin, 0.4 mg/kg, 4 properties). Samples were 
sealed in air-tight bags (expelling as much air as possible) and submitted to the laboratory by express post 
(maximum transit time = 3 days). We acknowledge that without vacuum packaging, truly anaerobic 
conditions cannot be created and some egg development may have been possible during transit (Nielsen et 
al., 2010; Sengupta et al., 2016). Post-treatment samples were collected on day 14 only from horses with a 
pre-treatment FEC of ≥150 epg. FECR (%) for each property was calculated according to American 
Association of Equine Practitioners (AAEP) Parasite Control Guidelines (Nielsen et al., 2016). Using the 
equation below, the FECR (%) for each horse in the group was calculated individually.  
 
Formula used to calculate FECR (%): 
[(FECpre – FECpost) / FECpre] x 100 
 
The mean reduction for all horses tested was then calculated to determine the percent reduction for the 
property. While equine-specific criteria are yet to be established to define the presence of ML-resistance, the 
AAEP Parasite Control Guidelines (Nielsen et al, 2016) recommend using a reduction of mean faecal egg 
count <95%. These guidelines are in line with the recommendations of the WAAVP (Coles et al., 1992) for 
FECRTs in sheep, which include a supporting criterion of a lower confidence limit (LCL) of < 90%. 
 
On three farms, further sampling was undertaken during Spring to determine the ERP following treatment 
with either MOX (1 farm) or IVM (2 farms). Faecal samples were collected from individual horses weekly 
from 2 weeks post-treatment until the ERP was reached. Faecal sampling ceased at 7, 8 and 12 weeks post-
treatment for properties A, B and C, respectively. ERP was defined as the period of time from treatment until 
the FECR (%) was ≤90% (von Samson-Himmelstjerna et al., 2007; Larsen et al., 2011; Nielsen et al., 2016). 
 
Comparisons among pre-treatment FEC of properties A, B and C were done using one way ANOVA 
(Kruskal-Wallis Test with Dunn's multiple comparison) (Graphpad Prism v6.05).  
 
3. Results 
The distribution of pre-treatment FECs was overdispersed and strongly skewed to the right (Fig 1), in line 
with what is typically observed in parasite count data (Crofton, 1971; Sreter et al., 1994; Galvani, 2003; 
Scheuerle et al., 2016).  
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Figure 1. Histogram showing the relative frequency of 419 pre-treatment faecal egg counts from 43 
properties.  
 
The 419 FEC values had a minimum of 150 epg, a median of 524 epg, a maximum of 4269 epg, and a mean 
± SE of 723 ± 33 epg. Only 17% of the values were < 200 epg. 
 
The mean percent reduction in FEC at 14 days post-treatment on all 42 properties surveyed was 100% 
following treatment with IVM, ABM or MOX. 
 
On the three properties where ERP was measured, pre-treatment FECs ranged from 236 – 1740 epg (mean 
667 epg, 95% CI 489-845, n=6) for property A, 181 – 2282 epg (mean 1107 epg, 95% CI 704–1510, n=18) 
for property B, and 359 – 918 epg (mean 741 epg, 95% CI 491-991, n=6) for property C (Figure 2), and were 
not significantly different (P=0.2356). 
 
For the IVM treatment properties (A and B), strongylid eggs were first detected in weeks 5 and 4, 
respectively, and the FECR threshold of 90% was reached between weeks 5 and 6 post-treatment for both 
properties, indicating an ERP of 6 weeks. For the MOX treatment group (property C), strongylid eggs were 
first detected at week 9 and the FECR was 90.4% at week 11, and had dropped to 81% by week 12 (Table 
2), indicating an ERP of 12 weeks.  
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Figure 2. Mean faecal egg counts (A) and faecal egg count reductions (B) showing 95% confidence intervals 
of three equine groups following treatment with either ivermectin (properties A and B) or moxidectin (property 
C). The 90% FECR threshold for defining the time when the official egg reappearance period has been 
reached is marked on (B) by the dashed red line. 
 
Table 2. Arithmetic mean faecal egg count reduction following treatment with ivermectin (0.2 mg/kg) 
(properties A and B) or moxidectin (0.4 mg/kg) (property C), and 95% confidence limits. 
Week post- 
treatment 
Faecal egg count reduction (%) 
a
 
A (IVM) B (IVM) C (MOX) 
2 100  100  100  
3 100  100  100  
4 100  94.8 (89.6-99.9) 100  
5 99.6 (98.8-100) 93.8 (88.3-99.3) 100  
6 80.4 (61.0-99.9) 76.8 (69.3-84.3) 100  
7 66.1 (29.3-100) 69.3 (49.0-83.6) 100  
8     100  
9     98.4 (95.5-100) 
10     98.8 (96.7-100) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 9 
11     90.4 (77.53-100) 
12     80.9 (57.3-100) 
a
 Bold indicates the week in which the egg reappearance period (defined as <90% FECR) was reached. 
 
4. DISCUSSION 
 
The FECRT results reported here are consistent with the findings of Pook and co-workers (2002) and show 
that ML drugs still remain effective against cyathostomins on the 43 properties examined, achieving a 100% 
reduction in FEC at 14 days post-treatment. ERPs measured on 3 properties, however, were shorter than 
those reported at the time of commercial release of ML anthelmintics, and are consistent with reports of 
shortened ERPs in other parts of the world. These findings indicate that ML products remain effective in 
treating existing cyathostomin populations, but there is cause for concern that ML-resistance may be 
emerging. 
 
Although these results show that ML drugs continue to be effective in treating Australian cyathostomins, 
evidence of emerging resistance is beginning to accumulate in the literature. A large European survey 
demonstrated IVM resistance on one Italian farm (46% faecal egg count reduction, or FECR; n=5 horses), 
and two UK farms (72% and 89% FECR; n=5 horses) (Traversa et al., 2009) and, similarly, Relf et al. (2014) 
reported an 85.7% FECR (n=6 horses) following IVM treatment on a UK farm. A brief report of <90% FECR 
14 days after IVM treatment has originated from Germany (Von Samson-Himmelstjerna et al., 2005) 
although precise information on group sizes on individual farms and methods used to calculated drug 
efficacy was not provided. In New Zealand, Bishop et al. (2014) reported an 84% FECR following treatment 
of 12 Thoroughbred weanling foals. Of particular concern are Brazilian field studies where a range of 
anthelmintics representing the three available drug classes all failed to reduce strongylid FECs by ≥90% 
Molento et al. (2008). These authors reported FECRs of 65%, 16%, 84% after treatment of horses (n=6) with 
IVM, MOX and ABM respectively. Combined with the additional findings that fenbendazole (FBZ, a BZ) and 
pyrantel (PYR, a THP) reduced FECs by just 18% and 7% respectively, these results provide evidence of 
multi-drug resistant cyathostomins present on a single farm. Similarly, Canever et al. (2013) reported FECRs 
of -18%, 59% and 89% for FBZ, PYR and IVM respectively on a single Brazilian farm. In such scenarios, 
options for worm control would become extremely limited.  
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Furthermore, there is growing evidence of reduced ML efficacy against other equine nematodes. There are 
numerous reports of Parascaris equorum resistance to MLs (Schougaard and Nielsen, 2007; Lyons et al., 
2008a; Veronesi et al., 2009; Armstrong et al., 2014; Bishop et al., 2014; Beasley et al., 2015), and growing 
concerns about ML efficacy against Oxyuris equi (Scháňková et al., 2013; Wolf et al., 2014; Felippelli et al., 
2015). Combined, these events highlight the danger of suppressive treatment regimes, still widely practiced 
on Australian horse properties, and underline the importance of routine monitoring of drug efficacy across 
farms. It has been estimated that by the time a FECRT can detect a reduction in drug efficacy, more than 
25% of the nematode population are resistant (Martin et al., 1989), so that appreciable levels of resistance 
may develop undetected at the farm level. Delaying changes to parasite control strategies until resistance is 
demonstrated via FECRT may be too little too late, since very little can be done to reverse the resistance 
status of a nematode population once established (Borgsteede and Duyn, 1989).  
 
There has been debate in the literature over the most appropriate method for statistical analysis of equine 
FECRT data. There are inherent difficulties in investigating anthelmintic efficacy of horses including; 
acquiring adequate group sizes with sufficiently high pre-treatment FECs; lack of untreated control groups; 
poor sensitivity and high variability of the FEC methodologies used; and the overdispersed nature of FEC 
data (Lester et al., 2013). Statistical analyses applied to FECR data have varied from calculating basic 
arithmetic group means (Coles et al., 1992) to the use of parametric bootstrap and likelihood-based 
analyses, or Bayesian parametric methods such as Markov chain Monte Carlo algorithms (Vidyashankar et 
al., 2012). The variation in reported statistical approaches highlights the need for consensus so that 
meaningful comparisons between papers can be made. In the absence of a clear consensus, the most 
widely used approach in recent literature, and outlined in the AAEP guidelines, has been adopted for use in 
the current study.  
 
A similar complication exists for comparing ERP results across multiple studies. Until the AAEP guidelines 
were published (Nielsen et al., 2016), a consensus on the precise definition of the ERP had not been 
reached. Earlier studies generally defined ERP as either the time taken for the mean FEC to exceed a 
predetermined threshold, usually in the range of 100 – 200 epg (Jacobs et al., 1995; Boersema et al., 1996; 
Mercier et al., 2001) or the time between anthelmintic treatment and the first positive FEC (Little et al., 2003; 
Molento et al., 2008, Fischer et al., 2015). Both methods are biased by individual differences in susceptibility 
to worm infection which are inherent in pre-treatment FECs. The AAEP recommendations, followed in the 
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current study, require horses be sampled weekly from 2 weeks post-treatment and define the ERP as the 
time when the mean FECR (%) first declines below 90% of the mean pre-treatment FEC. 
 
Shortly after the MLs became available on the Australian market, Rolfe et al. (1998) reported an 11-week 
ERP following IVM treatment of horses on a NSW property, and ERPs of similar length, (9-13 weeks), were 
also reported in Belgium and the Netherlands (Borgsteede et al., 1993; Boersema et al., 1996; 
Demeulenaere et al., 1997). More recently, however, there have been a number of reports of reduced ERPs 
following IVM treatment and ERPs of less than 8 weeks have been reported from the UK (Dudeney et al., 
2008; Relf et al., 2014; Hallowell-Evans et al., 2016), Germany (von Samson-Himmelstjerna et al., 2007), the 
USA (Little et al., 2003; Lyons et al., 2008b), and Sweden (Lind et al., 2007). In some of these studies, ERPs 
were as short as 4 weeks (Dudeney et al., 2008; Lyons et al., 2008b; Lyons et al., 2011) although there is a 
tendency for these shorter ERPs to reflect the time when strongylid eggs first reappeared in faeces following 
treatment, rather than when FECR (%) passed the 90% threshold as described earlier. In one UK study (et 
al., 2014), the first positive FEC was observed just 2 weeks after treatment of horses with IVM but the FECR 
had not decreased to ≤90% until week 6. Similarly, both Woods Jr et al. (1998) and Tarigo-Martinie et al. 
(2001) reported a ≤90% FECR at 6 weeks post IVM-treatment on US farms.  Although only two properties 
were examined in this study, our results mirror this trend, with the ERP following IVM treatment being 6 
weeks. 
 
MOX is generally considered to have an ERP of at least 14 – 16 weeks, and initial ERPs reported in 
Australia did exceed 14 weeks (Rolfe et al., 1998). ERPs exceeding 19 weeks were initially reported from 
Belgium and Canada (Slocombe and Lake, 1996; Demeulenaere et al., 1997), but, there have been a 
number of more recent reports indicating a dramatically shortened ERP. Rossano et al. (2010) reported only 
a 67% FECR at 6 weeks post MOX-treatment in a group of yearling horses in Kentucky. Similarly, Relf et al. 
(2014) reported ERPs following MOX administration of 6, 8 and 9 weeks respectively in 3 groups of horses in 
the UK. The ERP following MOX treatment reported here for property C was 11 weeks, shorter than the 14+ 
weeks originally reported. This indicates a shift toward decreasing ERP following MOX treatment on this 
Australian property, consistent with international observations  
 
There is a well-documented relationship between age and FEC in horses, with young animals having higher 
counts than mature horses (Klei and Chapman, 1999; Kornaś et al., 2010). There is also an assumption that 
ERPs are shorter in younger horses (Herd, 1986; Herd and Gabel, 1990), but the relationship between age 
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and ERP has not been thoroughly investigated and the evidence presented thus far is conflicting. Reasons 
proposed for a shorter ERP in young horses include the resumption of development of a higher number of 
encysted larvae, and higher rates of re-infection as a result of a less developed immune response. Hallowell-
Evans et al. (2016) carried out resistance testing (FECRTs) and ERP measurements on Thoroughbreds in 
the UK and asserted that young stock showed reduced FECRs following treatment with PYR compared to 
adults on the same farm. The ERPs for IVM and MOX were 6 and 8 weeks, respectively, however data from 
mature horses was not collected for comparison. Boersema et al. (1996) reported no significant difference in 
the ERPs of foals, yearlings and adult horses even though the FECs of the younger horses were consistently 
higher. Further investigations measuring ERP in both young and mature horses on the same farm are 
warranted to specifically test the hypothesis. Properties A and B in the present study differed markedly in the 
mean age of horses (mature/aged vs weanlings <1 year of age, respectively) but the younger cohort did not 
have significantly higher pre-treatment FECs than their mature counterparts, nor did they have a shorter 
ERP following treatment with IVM. Factors other than age and immunity are also known to influence FECs, 
such as the magnitude of larval challenge that horses are exposed to which is very difficult to quantify in the 
field. ERP measurement was carried out in the Spring for all 3 groups, a time of year in southeast QLD that 
provides favourable conditions for L3s on pasture, however no assumptions can be made about differences 
in larval challenge between the 3 properties. Although strongylid eggs were first detected one week earlier in 
the younger group (week 4 for property A versus week 5 for property B), the FECR threshold of 90% was 
reached in week 6 for both IVM-treated groups. In this case, it seems that age alone was not a useful 
predictor of ERP, however, it would be dangerous to extrapolate from such a limited dataset. Clearly, more 
work involving a larger number of Australian properties would be useful to further define the ERP following 
treatment with different ML products. Industry practice still largely involves suppressive treatment programs; 
apart from the inherent problems in such programs selecting for anthelmintic resistance, there is a significant 
risk that they are also based on incorrect assumptions about ERPs.  
 
The history of anthelmintic treatment frequency on a property may influence drug sensitivity of the resident 
cyathostomin population. Treatment frequency dictates the level of drug exposure to nematode populations 
and higher treatment frequencies select more strongly for resistance (Barton, 1983). Under this scenario, as 
the level of resistance increases, ERPs would potentially shorten. Properties A and B in the present study 
were grazed on properties with reported differences in historic ML treatment frequency. Property A had 
received infrequent ML treatments (1-2 times per year) for at least 10 years prior to the study, while 
management of horses on property B traditionally consisted of at least 4 ML treatments per year. Despite 
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this, the properties’ ERPs were similar, suggesting comparable reductions in drug sensitivity on both 
properties. Frequent movement of horses between properties, both locally, nationally and internationally for 
breeding and competition, is more common in the equine industry compared with production animal 
industries and has implications for the dispersal of resistance genes. In terms of anthelmintic resistance 
among cyathostomin populations, it could be speculated that the geographic dissemination of resistance 
genes between horse properties may be more significant than historic treatment frequency on a specific 
property. This would have implications for biosecurity protocols at equine events and more broadly for the 
general movement of horses on and off properties. Genetic studies would be required to examine this 
hypothesis further. 
 
Despite the encouraging FECRT results presented here, which provide evidence of continued high efficacy 
of the MLs against cyathostomins, there should be no complacency regarding the need for more strategic 
and targeted approaches to worm control. The shortening of ERPs reported here is a warning of impending 
resistance. There is a need for the development and adoption of more modern Australian parasite control 
guidelines, such as those provided by the AAEP (Nielsen et al., 2016). Surveillance of drug efficacy, along 
with routine monitoring of FECs, should form the foundation of such guidelines. In terms of identifying 
resistance at the earliest possible stage on properties where ML drugs have been shown to be 100% 
effective via FECRT, and in the absence of viable molecular or in vitro assays to assist, gathering ERP data 
is highly beneficial. The laborious and costly nature of weekly ERP sampling may be overcome by advising 
one additional sample at 4-6 weeks post-treatment. This would require further work on defining ERP 
thresholds for determining drug resistance status of cyathostomin populations, but is certainly a topic worthy 
of debate among equine parasitologists. 
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Table 1. Summary of 3 equine properties (A, B and C) recruited to measure strongylid egg reappearance 
period. 
Table 2. Arithmetic mean reductions in faecal egg count (FECR) following treatment with ivermectin (0.2 
mg/kg) or moxidectin (0.4 mg/kg) and 95% confidence limits in parentheses. 
 
Figure captions 
Figure 1. Histogram showing the relative frequency of 419 pre-treatment faecal egg counts from 43 
properties. 
Figure 2. Mean faecal egg counts (A) and faecal egg count reductions (B) showing 95% confidence intervals 
of three equine groups following treatment with either ivermectin (properties A and B) or moxidectin (property 
C). The 90% FECR threshold for defining the time when the official egg reappearance period has been 
reached is marked on (B) by the solid red line. 
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Highlights 
 Macrocyclic lactones remain 100% effective via FECRT on Australian horse farms. 
 Egg reappearance period following IVM was 6 weeks. 
 Egg reappearance period following MOX was 12 weeks. 
 Shortened ERPs likely reflect changing drug susceptibility of cyathostomins. 
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